
KEYNOTE-189 Updates Show Improved Outcomes for Metastatic Nonsquamous NSCLC Targeted Oncology
The phase III KEYNOTE-189 trial led to the FDA approval of the combination of pembrolizumab (Keytruda) plus chemotherapy for the treatment of patients with …
